Overview
Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida.
Dr. Carducci is rated as a Distinguished provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.
His clinical research consists of co-authoring 267 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Hormone Replacement Therapy (HRT).
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- EPO
- POS
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- EPO
- HMO
- POS
- PPO
- MEDICARE DISCOUNT CARD
- MEDICARE PDP
- OTHER MEDICARE
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
201 North Broadway Street, Viragh BLDG 5th FL, Viragh BLDG 5th FL, Baltimore, MD 21287
5255 Loughboro Road Northwest, Building B, Washington, DC 20016
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
11 Clinical Trials
Skip Viragh Outpatient Cancer Center
Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Urology at the Johns Hopkins University School of Medicine and Director of the Genitourinary Oncology Division for the Johns Hopkins Kimmel Cancer Center. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer. Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine. His research interests include prostate cancer, bipolar androgen therapy, clinical trials and targeted drug development. Dr. Denmeade has published over 200 papers in the area of prostate cancer research. He has received extensive funding from the NIH, the Department of Defense Prostate Cancer Research Fund and the Prostate Cancer Foundation. He is the Editor-in-Chief of the medical journal The Prostate. Dr. Denmeade is rated as a Distinguished provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy.
Sibley Memorial Hospital
Dr. Mark Markowski is a medical oncologist at the Kimmel Cancer Center at Sibley Memorial Hospital, as well as an Associate Professor in the Department of Oncology at Johns Hopkins University School of Medicine. Dr. Markowski participates in multidisciplinary clinics at Sibley and The Johns Hopkins Hospital, and sees patients in the genitourinary clinics of both hospitals. Dr. Markowski treats numerous types of cancers, with a specialty in prostate and kidney cancers. Dr. Markowski earned his medical degree and Ph.D. in tumor biology at Georgetown University School of Medicine. He completed a residency in internal medicine at Columbia University, followed by a medical oncology fellowship at Johns Hopkins Hospital. Dr. Markowski previously served as a research associate at the Lombardi Comprehensive Cancer Center at Georgetown University. His research interests focus on early phase drug development for prostate cancer, as well a non-castrating therapies for patients with metastatic disease. Dr. Markowski is currently conducting research with funding from a Department of Defense Prostate Cancer Research Program Award and a Challenge Award from the Prostate Cancer Foundation, which focuses on new treatment strategies for prostate cancer patients. Dr. Markowski is rated as a Distinguished provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Wilms Tumor 2, Hormone Replacement Therapy (HRT), and Prostatectomy.
Mario Eisenberger is an Oncologist in Baltimore, Maryland. Dr. Eisenberger is rated as a Distinguished provider by MediFind in Hormone Replacement Therapy (HRT). His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Familial Prostate Cancer, Hormone Replacement Therapy (HRT), and Prostatectomy.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- Chromophobe Renal Cell Carcinoma
- Familial Prostate CancerDr. Carducci isElite. Learn about Familial Prostate Cancer.
- Prostate CancerDr. Carducci isElite. Learn about Prostate Cancer.
- Renal Cell Carcinoma (RCC)Dr. Carducci isElite. Learn about Renal Cell Carcinoma (RCC).
- Distinguished
- Adult Soft Tissue SarcomaDr. Carducci isDistinguished. Learn about Adult Soft Tissue Sarcoma.
- Clear Cell SarcomaDr. Carducci isDistinguished. Learn about Clear Cell Sarcoma.
- Familial Wilms Tumor 2Dr. Carducci isDistinguished. Learn about Familial Wilms Tumor 2.
- Hormone Replacement Therapy (HRT)Dr. Carducci isDistinguished. Learn about Hormone Replacement Therapy (HRT).
- Wilms TumorDr. Carducci isDistinguished. Learn about Wilms Tumor.
- WT1-Related Wilms Tumor SyndromesDr. Carducci isDistinguished. Learn about WT1-Related Wilms Tumor Syndromes.
- Advanced
- Bone TumorDr. Carducci isAdvanced. Learn about Bone Tumor.
- Lung CancerDr. Carducci isAdvanced. Learn about Lung Cancer.
- NephrectomyDr. Carducci isAdvanced. Learn about Nephrectomy.
- OrchiectomyDr. Carducci isAdvanced. Learn about Orchiectomy.
- ProstatectomyDr. Carducci isAdvanced. Learn about Prostatectomy.
- Urothelial CancerDr. Carducci isAdvanced. Learn about Urothelial Cancer.
- Experienced
- AgranulocytosisDr. Carducci isExperienced. Learn about Agranulocytosis.
- Bladder CancerDr. Carducci isExperienced. Learn about Bladder Cancer.
- Breast CancerDr. Carducci isExperienced. Learn about Breast Cancer.
- Colorectal CancerDr. Carducci isExperienced. Learn about Colorectal Cancer.
- MelanomaDr. Carducci isExperienced. Learn about Melanoma.
- Multiple MyelomaDr. Carducci isExperienced. Learn about Multiple Myeloma.